Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial

By sjmartinez • May 30, 2025

Hu X, Curigliano G, Yonemori K, Bardia A, Barrios CH, Sohn J, Lévy C, Jacot W, Tsurutani J, Roborel de Climens A, Wu X, Andrzejuk-Ćwik A, Mbanya Z, Dent R. Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial. ESMO Open. 2025 May;10(5):105082. doi: 10.1016/j.esmoop.2025.105082. Epub 2025 May 15. PMID: 40441802.

Tags: Hematology/Oncology, HER2-low, metastatic breast cancer, patient-reported outcomes, Publications, Quality of Life, trastuzumab deruxtecan

Endometrial Serous Carcinoma Arising From Adenomyosis

Arzoo KK, Berkowitz MJ. Endometrial Serous Carcinoma Arising From Adenomyosis. Cureus. 2026 May 22;18(5):e109441. doi: 10.7759/cureus.109441. PMID: 42333330; PMCID: PMC13283456.

Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy

Othus M, Truong TG, Sharon E, Kendra K, Grossmann K, Buchbinder E, Khushalani NI, Eroglu Z, Chandra S, Doolittle GC, Kirkwood JM, Ikeguchi A, Mihalcioiu[...]

Mapping and engineering the human cell-cell interactome

Di Carlo D, Morsut L, McCain ML, Wright HJ, Abedi M, Yamada-Hunter SA, Zhang JZ, Backus K, Chung E, Wang Y, Rando TA, Cai L,[...]